Purpose. Saccharomyces boulardii may improve the immune response by enhancing the production of anti-inflammatory cytokines, T-cell proliferation and dendritic cell activation. The immunomodulator effect of this probiotic has never been tested with DNA vaccines, which frequently induce low antibody titers. This study evaluated the capacity of Saccharomyces boulardii to improve the humoral and cellular immune responses using DNA vaccines coding for the leptospiral protein fragments LigAni and LigBrep. BALB/c mice were fed with rodent-specific feed containing 10 8 c.f.u. of Saccharomyces boulardii per gram.
INTRODUCTION
DNA vaccines comprise cloning a gene coding for an antigen of interest in a eukaryotic expression plasmid, which is used to vaccinate animals whose cells will then express the antigen of the pathogen against which protection is sought [1] . This type of vaccine has been evaluated in several animal models for a number of bacterial [2, 3] , viral [4] [5] [6] [7] and parasitic diseases [8, 9] .
DNA vaccine stability and safety are greater than those of conventional vaccines because DNA is less prone to degradation, and there is no risk of disease infection. In addition, large-scale production and a high degree of purity are easily obtained at low cost [10] . In terms of efficiency, these vaccines can stimulate both the humoral and cellular responses for long periods [10] . However, they often induce low titres of antibodies [11] , resulting in the need for multiple immunizations [10] . This last point shows that the discovery of new safe and effective adjuvants or immunomodulators is fundamental for the development of more efficient DNA vaccines.
Immunomodulators and conventional adjuvants have the function of increasing the immune response, which can reduce the amount of antigen or number of immunizations required and, consequently, vaccination costs [12] . Probiotics are defined as live micro-organisms, which, when administered in adequate concentrations, are beneficial to host health [13] . Probiotic strains with immunostimulatory effects can increase the specific immune responses to antigens and are, therefore, promising as vaccine immunomodulators [14] [15] [16] [17] [18] . Saccharomyces boulardii is a well-known probiotic yeast but was not yet evaluated as immunomodulator for DNA vaccines. It can have an immunomodulatory effect by increasing anti-inflammatory cytokines, reducing levels of proinflammatory cytokines, stimulating the secretion of factors that modulate the restitution of gut cells and activating dendritic cells and the proliferation of T cells [19, 20] .
Leptospirosis is a neglected infectious disease of global importance and one of the greatest public health problems in Brazil [21, 22] . The proteins of the leptospiral immunoglobulin-like (Lig) family have been studied as antigens in recombinant vaccines [22, 23] . The objective of this study was to evaluate the ability of S. boulardii used as a probiotic feed supplement for mice, in order to boost the humoral and cellular immune responses of DNA vaccines using as immunogens the gene sequences encoding the leptospiral LigAni and LigBrep proteins.
METHODS
Micro-organisms and cultivation conditions S. boulardii was obtained from a commercial lyophilized product named Floratil (Merck), was recovered in yeast peptone dextrose (YPD) broth (yeast extract 1 %, peptone 2 % and Dglucose 2 %) and was incubated in an orbital shaker for 24 h (28 C; 200 r.p.m.). Then they were added to 7 L YPD broth and incubated in a bioreactor (Bioflo 110; New Brunswick Scientific) for 24 h (28 C; 500 r.p.m. 1 vvm) using antifoam 204 (Sigma-Aldrich). After fermentation, cells were recovered by centrifugation (15 min at 10, 000 Â g) and stored in saline solution (NaCl 0.9 %) at 4 C. Concentration of S. boulardii was determined by counting on YPD agar after incubation at 28 C for 48 h.
Escherichia coli BL21 (DE3) Star (Invitrogen) and E. coli TOP 10 (Invitrogen) were grown in Luria-Bertani (LB) broth (tryptone 1 %, yeast 0.5 % extract and NaCl 0.5 %) with 100 µg ml À1 ampicillin and incubated at 37 C for 18 h in an orbital shaker at 200 r.p.m.
Preparation of feed containing S. boulardii S. boulardii (10 8 c.f.u. g
À1
) was added to the rodent-specific, antibiotic-free, pre-ground diet (Supra). Viable counts were determined during the experiments by plating decimal yeast dilutions on YPD agar after incubation at 28 C for 48 h. This formulation was pelletized, dried in an oven with forced air circulation for 24 h at 40 C and stored at 4 C until further use [24] .
Construction of DNA vaccines
The construction of eukaryotic expression plasmids with ligAni gene (pTARGET/ligAni) and ligBrep (pTARGET/ligBrep) a the evaluation of their functionality were performed as described by Forster et al. [3] . The plasmids were obtained as previously described by Green and Sambrook [25] . Briefly, E. coli TOP 10 was transformed by heat shock with the plasmids pTARGET/ligAni and pTARGET/ligBrep, cultured in 500 ml of LB broth with 100 µg ml À1 ampicillin, 37 C, 200 r. p.m. until the mid-log growth phase (OD 600 , 0.6) and centrifuged at 2700 g for 15 min at 4 C. The pellet was suspended in 200 ml of STE buffer (Tris/HCl 0.2 M, NaCl 0.5 M, SDS 0.1 %, EDTA 0.01 M, pH 7.6), followed by another centrifugation under the same conditions. The supernatants were discarded, and the pellets were frozen at À20 C for 10 min. Thereafter, the pellets were thawed and stored for 5 min at room temperature and then suspended in 18 ml of solution I (glucose 50 mM, Tris/HCl 10 mM, RNAse 50 µg ml À1 , pH 7.4). To this, 40 ml of solution II (SDS 1 %, NaOH 0.2 M) was added and homogenized by inverting the tubes. Next, 20 ml of solution III (sodium acetate 3 M, pH 5.2) was added to the solution and vortexed. The tubes were centrifuged at 20 000 g for 30 min at 4 C, and approximately 45 ml of the supernatant was recovered and transferred to another tube, to which 27 ml of isopropanol was also added as well. After homogenization by inversion and storage for 15 min at room temperature, the tubes were centrifuged at 12 000 g for 15 min at the same temperature. The supernatant was discarded, and the pellets were washed with 70 % ethanol. After drying, the pellets were suspended in 3 ml TE (Tris/HCl 10 mM, pH 8.0, EDTA 1 mM). Plasmid DNA was quantified by electrophoresis on 0.8 % agarose gel, using l DNA/HindIII marker (Thermo Scientific) as reference, and frozen at À20 C until further use.
Expression and purification of recombinant proteins LigAni and LigBrep of Leptospira interrogans serovar Copenhageni, strain L1-130 in E. coli The construction of plasmids pAE/ligAni and pAE/ligBrep was performed by Forster et al. [3] . rLigAni and rLigBrep proteins were obtained as previously described by Green and Sambrook [25] . To this end, E. coli BL21 (DE3) Star was transformed by heat shock with the plasmids pAE/ligAni and pAE/ligBrep. The recombinant clones were selected on LB agar containing 100 µg ml À1 ampicillin and cultured in 500 ml LB broth at 37 C under shaking (250 r.p.m.) with ampicillin until the mid-log growth phase (OD 600 , 0.6-0.8).
Protein expression was induced with IPTG 0.5 mM at 37 C under agitation (200 r.p.m.) for 3 h and confirmed by Western blotting using anti-6xHis-tag antibody (Sigma-Aldrich).
rLigAni and rLigBrep proteins were recovered from inclusion bodies using urea (8 M). These proteins were purified by Ni 2+ -affinity chromatography HisTrap columns (GE Healthcare). Purified proteins were dialysed against PBS (pH 7.2, 4 C, 24 h) and quantified using BCA protein assay kit (Thermo Scientific Pierce) according to the manufacturer's instructions and stored at À20 C until further use.
Animals
Female BALB/c mice weighing 15 to 20 g were used. This study was conducted according to the Brazilian National Council for Animal Experimentation, and all animal procedures were approved by the Federal University of Pelotas Ethics Committee for Animal Experimentation (permit no. 7603). All animals were kept in facilities with 12 h lightdark cycle and temperature-controlled rooms. Food and water were available ad libitum, and all animals were under the care of a veterinarian. Bed (wood shavings) was exchanged daily. Animal health and comfort were assured by checking upon the animals three times a day. Signs used to monitor animal health were aggressive behaviour, mydriasis, tachycardia, tachypnea and muscle spasms. There were no unexpected deaths.
Evaluation of S. boulardii capacity to enhance the humoral and cellular immune responses in DNA vaccines
Four-to six-week-old mice were randomly divided into four groups containing 12 animals each. The animals of groups 1 and 3 were fed only feed without S. boulardii (control groups). The animals in groups 2 and 4 were fed an antibiotic-free diet containing S. boulardii (10 8 c.f.u. g
À1
). Mice were given feed containing the probiotic for 14 days prior to immunization and during the whole experiment [26] . To optimize the rational use and to reduce the number of animals used in the experiment, no negative control group inoculated with empty pTARGET plasmid was added, since this group had been evaluated earlier [3] . The immunization protocol consisted of three doses (days 0, 14 and 21). In order to enhance DNA absorption, sucrose 25 % (100 µl) was applied in the right hind limb approximately 45 min before immunization in all groups. In groups 1 and 2, immunization was performed with pTARGET/ligAni (100 µg), whereas groups 3 and 4 received the same dose of pTARGET/ligBrep. All inoculations were carried out intramuscularly.
One day before each immunization and week after the last (days À1, 13, 20 and 27), blood samples were collected from the retro-orbital venous plexus and incubated for 20 min at 37 C, followed by 1 h at 4 C, and centrifuged (10 min, 4,000 Â g) for serum collection to assess the humoral immune response. Serum samples were stored at À20 C until further use.
To evaluate the cellular immune response, animal blood samples were collected on the 37th day for RNA extraction using Gene JET whole blood RNA purification mini kit (Thermo Scientific), according to the manufacturer's instructions.
Evaluation of the humoral immune response ELISA with recombinant proteins was used to evaluate the humoral immune response. Microplates with 96 wells (CralPlast) were coated with 200 ng per well of either rLigAni (groups 1 and 2) or rLigBrep (groups 3 and 4) diluted in carbonate-bicarbonate buffer (0.05 M, pH 9.6). Then the sera of each animal, collected on days À1, 13, 20 and 27, were added, in duplicate, and diluted 1 : 30 in PBS plus 0.05 % Tween 20 (PBS-T). Sera from unvaccinated mice (day À1) were used as negative control. Peroxidase-conjugated goat anti-mouse polyvalent antibody (Sigma-Aldrich) was diluted in PBS-T (1 : 4,000) and added to each well. All reactions were performed for 1 h at 37 C using 50 µl reagents per well. Plates were washed three times after each step with PBS-T (200 µl per well). Reactions were developed by adding orthophenylenediamine in phosphate-citrate buffer (0.2 M, pH 4.0) and H 2 O 2 (0.01 %). Plates were maintained in the dark for 15 min at room temperature, and the OD 450 was read in a spectrophotometer for microplates. Antibody tits were expressed as ELISA units dividing the arithmetic mean of sera absorbance of each animal by the mean absorbance of each unvaccinated animals (day À1), expressing the results as total IgG fold increase [18] .
Cellular immune response evaluation
The cellular immune response was assessed according to the protocol described by Barjesteh et al. [27] , with modifications. Blood samples were collected 3 days after rLigAni or rLigBrep (50 µg) was intraperitoneally injected in the animals. Blood samples from each group were used to compose three pooled samples, containing 50 µl of blood from each animal. Total RNA was extracted using the Gene JET whole blood RNA purification mini kit (Thermo Scientific) and quantified using a NanoVue spectrophotometer (GE Healthcare UK Limited). For cDNA synthesis, we used 0.5 µg RNA and a High Capacity cDNA reverse transcription kit (Applied Biosystems). The quantitative realtime (qRT)-PCRs were performed using Stratagene Mx3005P real-time PCR system (Agilent Technologies), SYBR Green PCR Master Mix (Applied Biosystems) and the primers described in Table 1 [28] . The reaction conditions consisted of 95 C for 10 min; 40 cycles of 95 C for 15 s, 60 C for 60 s; and 72 C for 60 s. In addition, a dissociation curve ensured the specificity of the amplified products. All reactions were performed in duplicate. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used to normalize expression data of the target genes. Data were expressed in normalized cycle threshold (C T ) units. Briefly, the C T is the number of amplification cycles that were necessary to achieve a pre-defined threshold of fluorescence signal, which is proportional to the number of copies of the target cDNA region. Therefore, the C T is inversely proportional to the initial amount of the amplicon. The samples were analysed using the software REST 2009 [29] . The relative gene expression rate was calculated in relation to the GAPDH expression, as described by Pfaffl et al. [29] .
Statistics
Student's t-test was used to determine significant differences (P<0.05) between ELISA units of vaccinated and unvaccinated animals and between cytokine mRNA levels. All statistical analyses were performed using software Prism5 (GraphPad).
RESULTS

Production of DNA vaccines
Recombinant plasmids pTARGET/ligAni and pTARGET/ ligBrep were produced using E. coli TOP10. Extraction yielded up to 12 mg of each plasmid per lit of culture.
Expression of rLigAni and rLigBrep E. coli BL21 (DE3) Star effectively expressed rLigAni and rLigBrep recombinant proteins, since bands of 64 and 72 kDa, respectively, were detected by Western blot analysis (data not shown).
S. boulardii exerts an immunomodulator effect in DNA vaccines
Immunization with three DNA vaccine doses using S. boulardii as immunomodulator boosted the specific humoral immune response of both evaluated vaccines (Fig. 1) . The antibody levels of animals fed with S. boulardii and vaccinated with pTARGET/ligAni or pTARGET/ligBrep were higher after the second and third immunization (P<0.05), respectively, than those of control animals. In addition, there was no significant difference (P<0.05) in antibody levels between the second and third doses when pTARGET/ ligAni was used as immunogen. (Fig. 2) . A comparison of cytokine levels between control group and those using S. boulardii as immunomodulator showed a significant increase in IL-10 levels in the group using pTARGET/ ligBrep as antigen and S. boulardii as immunomodulator.
DISCUSSION
This study demonstrated that the probiotic S. boulardii is a promising immunomodulator, enhancing the humoral immune response of animals immunized with the gene sequences of the protein fragments LigAni and LigBrep of L. interrogans cloned in the plasmid pTARGET. These proteins were chosen as immunogens in view of their ability to enhance the immune response and protection in different studies, either as DNA vaccines or subunit vaccines [3, 23, [30] [31] [32] [33] . However, since vaccines using LigA as antigen may be too weak to eliminate the bacterium from the host tissue [30] , the immune response of these vaccines should be improved by immunomodulators.
Some studies using purified recombinant proteins containing immunoprotective epitopes failed to provide protection, probably due to errors in the conformation of important protective structures [34, 35] . Moreover, the subunit vaccine production is a challenge in terms of protein expression, purification and solubility [2] . On the other hand, DNA vaccines, easily produced and handled, are inexpensive and capable of inducing both humoral and cellular immune responses because the recombinant proteins are expressed host's cells, which also are capable of producing proteic antigens with the correct folding without requiring solubilization steps, resulting in closer similarity to the native conformation and greater cost-effectiveness [2, 36, 37] .
S. boulardii boosted the humoral immune response of DNA vaccines, since the antibody levels of animals fed with the yeast and vaccinated with pTARGET/ligAni or pTARGET/ ligBrep after the second and third immunizations, respectively, were higher (P<0.05) than those of animals in the control group.
The magnitude and direction of the antigen-specific cellular and humoral immune response can be modulated by using adjuvants or immunomodulators. When pTARGET/ ligBrep was used as a vaccine, a significant increase in the production of IL-10 by the animals in the group treated with S. boulardii over the control group was observed. This result corroborates the findings of a study that also evaluated LigB as immunogen in a subunit vaccine and aluminium as adjuvant [38] . An increase in IL-10 production was also found in response to the probiotic Bacillus cereus var. Toyoi in mice treated with an inactivated vaccine against bovine herpesvirus type 5 [18] and in mice that received S. boulardii orally and were then challenged with Candida albicans [39] .
Immunomodulation by means of probiotics was demonstrated by leukocyte proliferation, increase in phagocytic 2 -panel a) showed no difference between the control group and the group treated with S. boulardii on the 13th day after the first dose. However, after the second vaccination (day 20), the control group and treatment group differed statistically (P<0.05), which was maintained after the third dose on day 27. Groups immunized with pTARGET/ligBrep (groups 3 and 4 -panel b) showed no difference between the control group and the treatment group after the first and second doses on days 13 and 27, respectively. However, after the third dose (day 27), the titres of the treatment group were higher than those of the control group, with statistically significant differences (P<0.05). Plasmid pTARGET/ligBrep induced significantly higher antibody titres (P<0.05) after the third vaccination with S. boulardii than did pTARGET/ligAni. Data are represented as mean ELISA units of duplicates. An asterisk represents statistical difference (P<0.05).
activity, increased antibody production and changes in cytokine expression, of which the latter two actions were observed in this study. The use of S. boulardii is associated with an increase in anti-inflammatory cytokines, also observed in our study, as well as a reduction in proinflammatory cytokines, secretion of factors that modulate the restitution of gut cells, dendritic cell activation and Tcell proliferation [19, 20] . However, the exact mechanism of action is not fully understood. Moreover, in a study using the probiotics S. boulardii and B. cereus var. Toyoi, immunomodulation was triggered at the beginning of its administration, suggesting that the immune response to DNA vaccines can be increased without requiring S. boulardii administration over long periods, which would facilitate its use and reduce costs [40] .
A high protection level against lethal infection with leptospirosis in hamster was obtained with a subunit vaccine using LigA as immunogen and complete and incomplete Freund's adjuvant [23] . However, these adjuvants cause side effects such as granuloma growth, pain, sensitivity and erythema [41] . In DNA vaccines, the use of adjuvants is not related to total protection or reduction of infection [42, 43] . Moreover, the improvement obtained in the immune response is often restricted to the initial stage only [44] .
The results allowed the conclusion that the probiotic S. boulardii can enhance the humoral immune response to DNA vaccines, suggesting its potential as immunomodulator. In addition, one of the advantages of S. boulardii, non-pathogenic yeast with GRAS status, is the absence of adverse effects. Furthermore, its use as immunomodulator in DNA vaccines, aside from improving the specific humoral immune response against the antigen, has beneficial effects on the intestinal mucosa of the host (e.g. increases in the immune response, digestion, nutrient uptake and prevention or treatment of a number of intestinal disorders) [45] . Additionally, immunomodulators can allow a reduction in the amount of DNA used and, thereby, a reduction in the production cost, apart from enhancing the action of the vaccine and making it more effective. Thus, these results represent an important contribution in the field of vaccine development and pave the way for further investigations on S. boulardii as immunomodulator in DNA vaccines and as a probiotic. 
